Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?

Abstract

Breast cancer is the most common malignancy diagnosed in women worldwide, and hormone receptor-positive/HER2 (also known as ERBB2)-negative is the most common subtype, accounting for approximately 70% of all diagnoses [ 1 ]. Most cases are diagnosed at an early stage, thus being potentially curable with locoregional and systemic treatments. However, up to 20% of patients relapse in the first 10 years from diagnosis, with either locoregional or distant recurrences that are, in the latter case, incurable [ 2 ]. Therefore, research efforts have been focusing on testing new treatment strategies to reduce the risk of recurrence in these patients.

Topics & Concepts